Vernalis plc
From Wikipedia, the free encyclopedia
| Type | Public |
|---|---|
| Traded as | LSE: VER NASDAQ: VNLS |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Winnersh, United Kingdom |
| Key people | Ian Garland (CEO) Peter Fellner (Executive chairman) |
| Products | Frovatriptan, Apokyn |
| Employees | 200 |
| Website | www.vernalis.com |
Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]
The company has marketed two drug products; Frovatriptan,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.
[edit] References
- ^ "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 2003-07-03.
- ^ "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 2007-11-28.
- ^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. 07/2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.
- ^ "Apokyn". FDA. 2004. Retrieved 2004-07-29.[dead link]
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
